NCT02314247 · OUTCOME

Best Overall Response: Not Evaluable (NE)

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma · Source last updated 2023-01-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.

What was measured

Patients who could not be assessed quantitatively for disease response for any reason.

Analysis population: Intent to Treat population

Groups in this outcome

Selinexor (PTCL)

Assigned to 60 mg dose, 6 doses/cycle

Selinexor (CTCL)

Assigned to 60 mg dose, 6 doses/cycle (6 patients); Assigned to 60 mg dose, 8 doses/cycle (1 patient)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Selinexor (PTCL)	9
Selinexor (CTCL)	7

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Selinexor (PTCL)	4	Not reported	Not reported	Not reported	Not reported
Selinexor (CTCL)	2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
4
group Id
OG001
value
2

denoms

counts
group Id
OG000
value
9
group Id
OG001
value
7
units
Participants

description

Patients who could not be assessed quantitatively for disease response for any reason.

groups

description
Assigned to 60 mg dose, 6 doses/cycle
id
OG000
title
Selinexor (PTCL)
description
Assigned to 60 mg dose, 6 doses/cycle (6 patients); Assigned to 60 mg dose, 8 doses/cycle (1 patient)
id
OG001
title
Selinexor (CTCL)

param Type

COUNT_OF_PARTICIPANTS

population Description

Intent to Treat population

reporting Status

POSTED

time Frame

Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.

title

Best Overall Response: Not Evaluable (NE)

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice